Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -1721.80% is 10440% below its 4-year average of -16.34%, near the low end of its 4-year range (-1721.80%–3.11%).
1440.48% below its 12-month average of -111.77%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -322.92%.
RETURN ON EQUITY (ROE)
-1721.80%
RETURN ON EQUITY (ROE) AVG TTM
-111.77%
RETURN ON EQUITY (ROE) AVG 3Y
-22.46%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-1440.48%
CURRENT VS 3Y AVG
-7567.07%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.20%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
-4079.13%
vs the sector median at left
ARS Pharmaceuticals, Inc.
Market Cap
$424.52M
Return on Equity (ROE)
-1721.80%
TTM Avg
-111.77%
3Y Avg
-22.46%
5Y Avg
N/A
Market Cap
$424.40M
Return on Equity (ROE)
-9.23%
TTM Avg
-76.14%
3Y Avg
-50.80%
5Y Avg
-36.67%
Market Cap
$416.27M
Return on Equity (ROE)
-121.12%
TTM Avg
180.84%
3Y Avg
-1331.02%
5Y Avg
-839.91%
Market Cap
$428.21M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
Market Cap
$429.82M
Return on Equity (ROE)
-70.24%
TTM Avg
-381.56%
3Y Avg
-217.03%
5Y Avg
-155.40%
Market Cap
$411.20M
Return on Equity (ROE)
14.40%
TTM Avg
1.26%
3Y Avg
-7.83%
5Y Avg
-9.02%
Market Cap
$431.63M
Return on Equity (ROE)
-38.32%
TTM Avg
-35.34%
3Y Avg
12.60%
5Y Avg
10.50%
Market Cap
$409.43M
Return on Equity (ROE)
-37.05%
TTM Avg
-58.80%
3Y Avg
-40.96%
5Y Avg
-32.01%
Market Cap
$407.30M
Return on Equity (ROE)
-28.18%
TTM Avg
-0.06%
3Y Avg
10.58%
5Y Avg
10.58%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | $424.52M | -1721.80% | -111.77% | -22.46% | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $424.40M | -9.23% | -76.14% | -50.80% | -36.67% |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | -121.12% | 180.84% | -1331.02% | -839.91% |
| NeoGenomics, Inc. (NEO)vs › | $428.21M | -6.60% | -10.82% | -11.36% | -7.59% |
| Editas Medicine, Inc. (EDIT)vs › | $429.82M | -70.24% | -381.56% | -217.03% | -155.40% |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.20M | 14.40% | 1.26% | -7.83% | -9.02% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $431.63M | -38.32% | -35.34% | 12.60% | 10.50% |
| Myriad Genetics, Inc. (MYGN)vs › | $409.43M | -37.05% | -58.80% | -40.96% | -32.01% |
| Shoulder Innovations, Inc. (SI)vs › | $407.30M | -28.18% | -0.06% | 10.58% | 10.58% |
| Prothena Corporation plc (PRTA)vs › | $410.17M | -15.33% | -56.08% | -39.28% | -33.86% |
ROE
-1721.8%
ROA
-86.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -322.92% |
| 2025-12-31 | -149.92% |
| 2025-09-30 | -54.21% |
| 2025-06-30 | -24.97% |
| 2025-03-31 | -6.83% |
| 2024-12-31 | 3.11% |
| 2024-09-30 | -24.43% |
| 2024-06-30 | -20.83% |
| 2024-03-31 | -22.20% |
| 2023-12-31 | -23.56% |
| 2023-09-30 | -25.97% |
| 2023-06-30 | -21.46% |
| 2023-03-31 | -16.23% |
| 2022-12-31 | -12.71% |
| 2022-09-30 | -98.10% |
| 2022-03-31 | -7.79% |
| 2021-09-30 | -8.49% |
